Home・Список акций・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Закрыт

СекторЗдравоохранение

13.25 3.27

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

12.53

Макс.

13.62

Ключевые показатели
By Trading Economics
Доход	-1.2M -13M
Продажи	-1.5M 17M
Прибыль на акцию	-0.45
Рентабельность продаж	-76.292
Сотрудники	120
EBITDA	-958K -8.6M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+54.44% upside

Дивиденды
By Acuity
Следующий отчет о доходах	7 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-52M 370M
Предыдущая цена открытия	9.98
Предыдущая цена закрытия	13.25

Новостные настроения

By Acuity

31%

69%

97 / 340 Рейтинг в Healthcare

ENANTA PHARMACEUTICALS INC График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31 июл. 2026 г., 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30 июл. 2026 г., 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29 июл. 2026 г., 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28 июл. 2026 г., 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27 июл. 2026 г., 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24 июл. 2026 г., 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21 июл. 2026 г., 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 июл. 2026 г., 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Сравнение c конкурентами

Изменение цены

ENANTA PHARMACEUTICALS INC Прогноз

Целевая цена

By TipRanks

54.44% рост

Прогноз на 12 месяцев

Средняя 20 USD 54.44%

Максимум 20 USD

Минимум 20 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для ENANTA PHARMACEUTICALS INC на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

1 ratings

Покупка

Удержание

Продажа

Основано на мнении 1 аналитиков, присваивавших рейтинги акциям ENANTA PHARMACEUTICALS INC – Данные за последние 3 месяца.

Настроения

By Acuity

97 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.